WAM
TGTX icon

Wolverine Asset Management’s TG Therapeutics TGTX Stock Holding History

Wolverine Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,240
Closed -$125K – 2352
2021
Q2 		$125K Buy
+3,240
New +$127K ﹤0.01% 1406
2021
Q1 		– Sell
-471
Closed -$24K – 2270
2020
Q4 		$24K Buy
+471
New +$15.9K ﹤0.01% 1427

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Asset Management's TGTX Position: Q3 2021 in Review

Wolverine Asset Management sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 3,240 shares — an estimated $125K sold.

Wolverine Asset Management first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $125K in Q2 2021. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Wolverine Asset Management reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 3,240 TG Therapeutics shares in Q3 2021, an estimated $125K.
  • Wolverine Asset Management first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
  • Wolverine Asset Management's TG Therapeutics position peaked at $125K in Q2 2021.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.